Pfizer And Lpath To Partner On Antibody For Wet Age-Related Macular Degeneration
This article was originally published in The Pink Sheet Daily
Executive Summary
Option deal provides $14 million upfront plus cost-sharing arrangement for previously cash-strapped biotech.
You may also be interested in...
FDA Lifts Clinical Hold On Lpath’s Wet-AMD Drug Isonep
The San Diego biotech gets clearance from regulatory authorities to restart Phase II trials for its lead compound after a clinical hold delayed progress.
Financings Of The Fortnight: More IPOs But More Haircuts As Well
Initial public offerings by life sciences companies spanned the alphabet over the past two weeks, but each of three IPOs had one common factor - significant discounts in opening share prices.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.